贝达喹啉耐药及耐药诊断的研究进展  

Research progress on bedaquiline resistance and drug resistance diagnosis

作　　者：杨子仪 陈素婷[1] Yang Ziyi;Chen Suting(National Clinical Laboratory on Tuberculosis,Beijing Key Laboratory for Drug-resistant Tuberculosis Research,Beijing Chest Hospital,Capital Medical University/Beijing Tuberculosis and Thoracic Tumor Institute,Beijing 101149,China)

机构地区：[1]国家结核病临床实验室,耐药结核病研究北京市重点实验室,首都医科大学附属北京胸科医院/北京市结核病胸部肿瘤研究所,北京101149

出　　处：《中国防痨杂志》2025年第3期374-379,共6页Chinese Journal of Antituberculosis

基　　金：北京市通州区科技创新人才杰出青年科技工作者(JCQN2024013)。

摘　　要：贝达喹啉是一种二芳基喹啉化合物,是用于治疗利福平耐药结核病和耐多药结核病的新型抗结核药物。自从批准使用以来,贝达喹啉已显著提高了耐药结核病的治疗效果。然而,随着该药物的广泛使用,贝达喹啉耐药发生及耐药监测成为了一个备受关注的临床问题。笔者分析了贝达喹啉耐药分子机制、耐药表型及基因型的诊断方法,以期为贝达喹啉的临床使用及耐药监测管理提供参考。Bedaquiline,a diarylquinoline compound,is a novel anti-tuberculosis drug used for treatment of rifampicin-resistant and multi-drug resistant tuberculosis.Since its approval,bedaquiline has significantly improved anti-tuberculosis treatment outcomes.However,with its widespread usage,the emergence of bedaquiline resistance and its monitoring have become critical clinical concerns.This paper reviews molecular mechanisms of bedaquiline resistance,methods for identifying different resistance phenotypes and genotypes,aiming to provide insights for the clinical usage of bedaquiline and the monitoring and management of resistance.

关 键 词：结核 抗药性 诊断 

分 类 号：R3[医药卫生—基础医学] Q93[生物学—微生物学]